AVROBIO (NASDAQ:AVRO) Trading Down 1.4%

AVROBIO, Inc. (NASDAQ:AVRO) shares dropped 1.4% during trading on Tuesday . The stock traded as low as $1.38 and last traded at $1.40. Approximately 206,800 shares were traded during mid-day trading, a decline of 23% from the average daily volume of 269,831 shares. The stock had previously closed at $1.42.

AVROBIO Trading Down 1.4 %

The company has a market cap of $62.85 million, a price-to-earnings ratio of 2.03 and a beta of 1.23. The firm has a 50-day moving average price of $11.90 and a 200 day moving average price of $14.34.

AVROBIO (NASDAQ:AVRO) last issued its earnings results on Thursday, May 9th. The company reported ($1.80) EPS for the quarter. Research analysts anticipate that AVROBIO, Inc. will post -0.48 earnings per share for the current fiscal year.

Insider Activity at AVROBIO

In related news, major shareholder Braden Michael Leonard acquired 39,146 shares of AVROBIO stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $587,190.00. Following the transaction, the insider now directly owns 372,615 shares of the company’s stock, valued at approximately $5,589,225. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in AVROBIO by 17.4% during the 1st quarter. Vanguard Group Inc. now owns 1,881,234 shares of the company’s stock valued at $2,408,000 after purchasing an additional 279,400 shares during the period. Ikarian Capital LLC boosted its position in AVROBIO by 5.0% during the 1st quarter. Ikarian Capital LLC now owns 754,061 shares of the company’s stock worth $965,000 after acquiring an additional 35,802 shares during the period. Affinity Asset Advisors LLC boosted its position in AVROBIO by 40.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 700,000 shares of the company’s stock worth $896,000 after acquiring an additional 200,000 shares during the period. Vazirani Asset Management LLC boosted its position in AVROBIO by 38.8% during the 4th quarter. Vazirani Asset Management LLC now owns 650,000 shares of the company’s stock worth $884,000 after acquiring an additional 181,727 shares during the period. Finally, FNY Investment Advisers LLC boosted its position in AVROBIO by 77.8% during the 4th quarter. FNY Investment Advisers LLC now owns 400,000 shares of the company’s stock worth $544,000 after acquiring an additional 175,000 shares during the period. Institutional investors and hedge funds own 62.63% of the company’s stock.

About AVROBIO

AVROBIO, Inc, a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.